

Public

Environmental and Social Data Sheet

Overview

Project Name:	NIGHTINGALE (EGFF)
Project Number:	2018-0155
Country:	Finland
Project Description:	The project concerns investments into research and development and related capital expenditure activities in the field of blood analysis to provide solutions for chronic disease detection and prevention.
EIA required:	No
Project included in Carbon Footprint Exercise:	No

Environmental and Social Assessment

Environmental Assessment

Nightingale (the promoter) is an innovative blood analysis company established in 2013 in Helsinki, Finland. Leveraging on a strong internal expertise in NMR (Nuclear Magnetic Resonance), metabolomics technology and IT software developers, the promoter has developed proprietary NMR based spectroscopy technology to simultaneously analyse 220+ blood biomarkers from a single sample with unique price and quality level. In routine clinical practice, a metabolic profile that provides a “bird’s eye view” of a person’s health can be generated by using Nightingale’s proprietary diagnostic methods and equipment.

The promoter’s investments that are to be financed concern research, development and innovation activities that will be in the pharmaceutical and biotechnology sectors, enabling the company to further develop its analysis technology (automated NMR measurements, data management, data integration, etc) allowing omics blood measurements to be brought to routine risk prediction and early diagnosis procedures across multiple indications.

The project’s activities are not listed in any of the annexes of the EU Directive 2011/92/EU as amended by 2014/52/EU. Furthermore, the project will be carried out in existing facilities already authorised for similar activities and volumes. Therefore, an Environmental Impact Assessment (EIA) is not required.

The promoter’s R&D facilities and practices are in compliance with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices including adherence to ISO13485 and ISO14001. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU.

Luxembourg, 29 June 2018

Social Assessment, where applicable

The project, if successful, is expected to lead to important social benefits stemming from its focus on the development of novel innovative blood analysis approaches. The project aims to guide clinicians in deciding who should receive different drug treatments for diabetes and Cardio Vascular Diseases, and to detect minute changes in a patient's blood that may signal the risk of developing other diseases (e.g. non-alcoholic fatty liver disease).

Through the R&D activities and investments, the promoter expects to sustain and even increase its current level of highly skilled personnel, while contributing to reinforce European scientific innovation and knowledge base, hence fostering and nurturing the vital research community in the in vitro diagnosis space.

Other Environmental and Social Aspects

Nightingale has a sound Safety Health and Environment (SHE) policy, including a commitment to comply with legal requirements, pollution prevention, continual improvements and undertakes regular audits.

Conclusions and Recommendations

Overall, the project can be classified as acceptable with positive or no residual impact. Moreover, if successful the project presents high potential health and social benefits for society. The project is therefore considered acceptable for EIB financing.

PJ/SQM/ECSO 15.10.15